An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Inflammatory Myopathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Sjogren ' s Syndrome Interventions: Other: YTS109 Sponsors: China Immunotech (Beijing) Biotechnology Co., Ltd.; Shanghai Changzheng Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)
Conditions: Refractory Lupus Nephritis Interventions: Biological: TAK-007; Drug: Chemotherapy Agents Sponsors: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Other: Electroencephalography (EEG) signals, which will be detected noninvasively from dry scalp surface electrodes while the subjects are in a state of wakeful rest. Sponsors: Northwell Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Phase 1 Study of ADI-001 in Lupus Nephritis
Conditions: Lupus Nephritis; Autoimmune Diseases Interventions: Drug: ADI-001; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Adicet Bio, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus
Conditions: Lupus Erythematosus, Systemic Interventions: Biological: ATHENA CAR-T; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: EdiGene Inc.; The First Affiliated Hospital of Henan University of Science and Technology; Changping Laboratory Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus (SLE); Sjogren ' s Syndrome; Systemic Sclerosis; Inflammatory Myopathy; ANCA Associated Vasculitis; Antiphospholipid Syndrome Interventions: Biological: Anti-CD19-CD3E-CAR-T cells Sponsors: Shanghai Changzheng Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique
Conditions: Systemic Lupus Erythematosus; Renal Disease Interventions: Other: Blood sample for analysis of plasma of organochlorine pesticides concentration; Other: Blood sample for cell collection Sponsors: University Hospital Center of Martinique; Institut Pasteur de Guadeloupe; Centre de Ressources Biologiques de la Martinique (CeRBiM) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathies; Systemic Sclerosis; IgG4 Related Disease; Primary Sj ögren Syndrome Interventions: Biological: T cell injection targeting CD19 chimeric antigen receptor Sponsors: PersonGen BioTherapeutics (Suzhou) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Drug: Sulfasalazine Tablets Sponsors: Qiong Fu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Biological: Blood sample; Drug: Treatment :Abacavir 600 mg/lamivudine 300 mg; Other: Lupus Impact Tracker questionnaire Sponsors: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus; Lupus Nephritis; Autoimmune Diseases; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatous Polyangiitis; Microscopic Polyangiitis; Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Sjogren ' s Syndrome Interventions: Biological: CD19- BCMA CAR-T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Biological: CD19/BCMA Hi-TCR-T cell therapy Sponsors: Wuhan Union Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Dermatomyositis; Polymyositis Interventions: Drug: anti-CD19 CAR T cell therapy Sponsors: University of Erlangen-N ürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)
Conditions: Lupus Nephritis; Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV Interventions: Biological: KYV-101 anti-CD19 CAR-T cell therapy; Drug: Standard lymphodepletion regimen Sponsors: Kyverna Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus Interventions: Biological: LMY-920 Sponsors: Luminary Therapeutics; Nationwide Children Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
